Relapsing and progressive forms of multiple sclerosis: Insights from pathology

Current Opinion in Neurology

Volumn 27, Issue 3, 2014, Pages 271-278

  Dutta, Ranjan ^a   Trapp, Bruce D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

axons; multiple sclerosis; myelin; neurons

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; CALCIUM CHANNEL N TYPE; CYTOKINE; FREE RADICAL; MATRIX METALLOPROTEINASE; METABOTROPIC RECEPTOR; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN PROTEIN; N METHYL DEXTRO ASPARTIC ACID; PROTEOLIPID PROTEIN;

APOPTOSIS; B LYMPHOCYTE; BLOOD BRAIN BARRIER; BRAIN CORTEX LESION; CELL DEATH; DEMYELINATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GLIOSIS; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIA; PATHOGENESIS; RELAPSE; REVIEW; WHITE MATTER LESION; BRAIN; BRAIN CORTEX; GRAY MATTER; PATHOLOGY; WHITE MATTER;

BRAIN; CEREBRAL CORTEX; DISEASE PROGRESSION; GRAY MATTER; HUMANS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; WHITE MATTER;

EID: 84900474913     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000094     Document Type: Review

References (90)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52:61-76.
2. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399:A40-A47.
3. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31:247-269.
4. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1998; 36:S6-S11.
5. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141:554-555; 557-558.
6. Prineas JW, McDonald WI, Franklin RJM. Demyelinating diseases. In: Graham DI, Lantos PL, editors. Greenfield's neuropathology, 7th ed. New York: Oxford University Press; 2002. pp. 471-535.
7. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8:280-291.
8. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7:841-851.
9. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr Opin Neurol 2011; 24:224-229.
10. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degeneration-recent insights from MS pathology. Biochim Biophys Acta 2011; 1812:275-282.
11. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
12. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008; 63:16-25.
13. Trapp BD, Bo L, Mork S, Chang A. Pathogenesisoftissue injury in MSlesions. J Neuroimmunol 1999; 98:49-56.
14. Matthews PM, De SN, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18:327-336.
15. Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011; 259:659-681.
16. Napoli SQ, Bakshi R. Magnetic resonance imaging in multiple sclerosis. Rev Neurol Dis 2005; 2:109-116.
17. Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005; 15:46S-57S.
18. Tartaglia MC, Arnold DL. The role of MRS and fMRI in multiple sclerosis. Adv Neurol 2006; 98:185-202.
19. Filippi M, Rocca MA. Functional MR imaging in multiple sclerosis. Neuro-imaging Clin N Am 2009; 19:59-70.
20. Filippi M, Rocca MA, De SN, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 2011; 68:1514-1520.
21. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler 2002; 8:93-97.
22. Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013; 333:1-4.
23. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285.
24. Kornek B, Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999; 9:651-656.
25. Kornek B, Storch MK, Bauer J, et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001; 124:1114-1124.
26. Geurts JJ, Wolswijk G, Bo L, et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003; 126: 1755-1766.
27. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123:1174-1183.
28. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007; 68:S22-S31.
29. Giuliani F, Yong VW. Immune-mediated neurodegeneration and neuroprotection in MS. Int MS J 2003; 10:122-130.
30. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult Scler 1998; 4:93-98.
31. Nave K-A, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31:535-561.
32. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233:3-13.
33. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006; 53:212-224.
34. Karadottir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438:1162-1166.
35. Salter MG, Fern R. NMDA receptors are expressed in developing oligoden-drocyte processes and mediate injury. Nature 2005; 438:1167-1171.
36. Micu I, Jiang Q, Coderre E, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006; 439:988-992.
37. Ouardouz M, Coderre E, Zamponi GW, et al. Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol 2009; 65:160-166.
38. Ouardouz M, Coderre E, Basak A, et al. Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 2009; 65:151-159.
39. Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci 2000; 20: 1190-1198.
40. Tekkok SB, Goldberg MP. AMPA/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci 2001; 21:4237-4248.
41. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65:239-248.
42. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393-404.
43. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 2004; 101:2428-2433.
44. Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194:669-676.
45. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159:809-815.
46. Khoury SJ, Guttmann CR, Orav EJ, et al. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 2000; 57:1183-1189.
47. Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuro-pharmacol 2009; 32:121-132.
48. + T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004; 103:4222-4231.
49. Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol 2003; 4:503-505.
50. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration inmultiple sclerosis: relationshipto neurological disability. Neuroscientist 1999; 5:48-57.
51. Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007; 62:219-228.
52. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
53. Nave KA. Myelination and the trophic supportof long axons. Nat Rev Neurosci 2010; 11:275-283.
54. Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998; 18:1953-1962.
55. Klugmann M, Schwab MH, Puhlhofer A, et al. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 1997; 18:59-70.
56. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003; 33:366-374.
57. Bechtold DA, Smith KJ. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 2005; 233:27-35.
58. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol 2007; 17:230-242.
59. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2006; 7:932-941.
60. Ames A III. CNS energy metabolism as related to function. Brain Res Brain Res Rev 2000; 34:42-68.
61. Mahad D, Lassmann H, Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 2008; 34:577-589.
62. Mahad D, Ziabreva I, Lassmann H, Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008; 131:1722-1735.
63. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132:1161-1174.
64. Black JA, Newcombe J, Trapp BD, Waxman SG. Sodium channel expression within chronic multiple sclerosis plaques. J Neuropathol Exp Neurol 2007; 66:828-837.
65. + ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008; 63:428-435.
66. Bo L, Vedeler CA, Nyland HI, et al. Subpial demyelinationinthe cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003; 62:723-732.
67. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128:2705-2712.
68. Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11:1082-1092.
69. Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003; 126:1734-1744.
70. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to longterm disability in multiple sclerosis. Ann Neurol 2008; 64:247-254.
71. Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons and reduced inflammation in cortical MS lesions. Ann Neurol 2001; 50:389-400.
72. Lassmann H. Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration. Brain 2012; 135:2904-2905.
73. Bo L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003; 9:323-331.
74. Bo L, Geurts JJ, van der Valk V, et al. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 2007; 64:76-80.
75. Kooi EJ, Strijbis EM, van der Valk P, Geurts JJ. Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathologic implications. Neurology 2012; 79:1369-1376.
76. Antel J, Antel S, Caramanos Z, et al. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuro-pathol 2012; 123:627-638.
77. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647-656.
78. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demye-lination in early multiple sclerosis. N Engl J Med 2011; 365:2188-2197.
79. Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 2006; 245:123-126.
80. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68:477-493.
81. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130:1089-1104.
82. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134:2755-2771.
83. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012; 12:11.
84. Kooi EJ, Geurts JJ, van horssen J, et al. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. J Neu-ropathol Exp Neurol 2009; 68:1021-1028.
85. Walker CA, Huttner AJ, O'Connor KC. Cortical injury in multiple sclerosis; the role of the immune system. BMC Neurol 2011; 11:152.
86. Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol 2012; 72:918-926.
87. Franklin RJ, ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012; 8:624-634.
88. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007; 7:239-244.
89. Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007; 33:86-98.
90. van Horssen J, Brink BP, De Vries HE, et al. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007; 66:321-328.